Education
About Us
Working with TipRanks
Follow Us
Beximco Pharmaceuticals Limited Sponsored GDR RegS (GB:BXP)
LSE:BXP
| Jun 23 | Jun 22 | Jun 21 | Jun 20 | Jun 19 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | |||||
| Gross Profit | $ 17.31B | $ 41.14B | $ 13.92B | $ 11.90B | $ 10.62B |
| Operating Income | $ 7.17B | $ 19.78B | $ 6.66B | $ 5.51B | $ 4.87B |
| EBITDA | $ 9.37B | $ 27.12B | $ 7.18B | $ 5.64B | $ 4.93B |
| Net Income | $ 4.61B | $ 21.34B | $ 5.13B | $ 3.51B | $ 3.03B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ ― | $ ― | $ ― | $ ― | $ ― |
| Total Assets | $ 62.59B | $ 179.08B | $ 52.25B | $ 50.12B | $ 49.21B |
| Total Debt | $ 10.07B | $ 35.41B | $ 7.63B | $ 10.50B | $ 13.48B |
| Net Debt | $ 9.13B | $ 32.97B | $ 6.96B | $ 9.87B | $ 12.55B |
| Total Liabilities | $ 19.25B | $ 58.14B | $ 14.88B | $ 17.32B | $ 19.35B |
| Stockholders' Equity | $ ― | $ ― | $ ― | $ ― | $ ― |
| Cash Flow | |||||
| Free Cash Flow | $ 3.55B | $ 6.62B | - | - | - |
| Operating Cash Flow | $ 6.08B | $ 15.08B | $ 6.02B | $ 5.54B | - |
| Investing Cash Flow | |||||
| Financing Cash Flow |
Beximco Pharmaceuticals Limited Sponsored GDR RegS Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.